Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery

被引:100
|
作者
Tzeyung, Angeline Shak [1 ]
Md, Shadab [2 ,3 ]
Bhattamisra, Subrat Kumar [4 ]
Madheswaran, Thiagarajan [2 ]
Alhakamy, Nabil A. [3 ]
Aldawsari, Hibah M. [3 ]
Radhakrishnan, Ammu K. [5 ]
机构
[1] Int Med Univ, Sch Postgrad Studies, Kuala Lumpur 57000, Malaysia
[2] Int Med Univ, Sch Pharm, Dept Pharmaceut Technol, Kuala Lumpur 57000, Malaysia
[3] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21589, Saudi Arabia
[4] Int Med Univ, Sch Pharm, Dept Life Sci, Kuala Lumpur 57000, Malaysia
[5] Int Med Univ, Sch Med, Dept Pathol, Kuala Lumpur 57000, Malaysia
来源
PHARMACEUTICS | 2019年 / 11卷 / 01期
关键词
chitosan; nanoparticles; nose to brain; Parkinson disease; rotigotine; DRUG-DELIVERY; PLGA NANOPARTICLES; FORMULATION; SYSTEM; AGENTS;
D O I
10.3390/pharmaceutics11010026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the present study was to develop, optimize, and evaluate rotigotine-loaded chitosan nanoparticles (RNPs) for nose-to-brain delivery. Rotigotine-loaded chitosan nanoparticles were prepared by the ionic gelation method and optimized for various parameters such as the effect of chitosan, sodium tripolyphosphate, rotigotine concentration on particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The prepared nanoparticles were characterized using photon correlation spectroscopy, transmission electron microscopy, scanning electron microscopy, atomic force microscopy, fourier-transform infrared spectroscopy, and X-ray diffraction. The developed RNPs showed a small hydrodynamic particle size (75.37 +/- 3.37 nm), small PDI (0.368 +/- 0.02), satisfactory zeta potential (25.53 +/- 0.45 mV), and very high entrapment efficiency (96.08 +/- 0.01). The 24-h in vitro release and ex vivo nasal permeation of rotigotine from the nanoparticles were 49.45 +/- 2.09% and 92.15 +/- 4.74% while rotigotine solution showed corresponding values of 95.96 +/- 1.79%and 58.22 +/- 1.75%, respectively. The overall improvement ratio for flux and permeability coefficient were found to be 4.88 and 2.67 when compared with rotigotine solution. A histopathological study showed that the nanoparticulate formulation produced no toxicity or structural damage to nasal mucosa. Our results indicated that rotigotine-loaded chitosan nanoparticles provide an efficient carrier for nose-to-brain delivery.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma
    Dias, Amanda de Fraga
    Dallemole, Danieli Rosane
    Bruinsmann, Franciele Aline
    Lopes Silva, Luiz Fernando
    Cruz-Lopez, Olga
    Conejo-Garcia, Ana
    Oliveira Battastini, Ana Maria
    Maria Campos, Joaquin
    Guterres, Silvia Staniscuaski
    Pohlmann, Adriana Raffin
    Figueiro, Fabricio
    NANOMEDICINE, 2021, 16 (23) : 2095 - 2115
  • [32] Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery
    Piazzini, Vieri
    Landucci, Elisa
    D'Ambrosio, Mario
    Fasiolo, Laura Tiozzo
    Cinci, Lorenzo
    Colombo, Gaia
    Pellegrini-Giampietro, Domenico E.
    Bilia, Anna Rita
    Luceri, Cristina
    Bergonzi, Maria Camilla
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 129 : 267 - 280
  • [33] Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery
    Salade, Laurent
    Wauthoz, Nathalie
    Vermeersch, Marjorie
    Amighi, Karim
    Goole, Jonathan
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 129 : 257 - 266
  • [34] Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery
    Salade, Laurent
    Wauthoz, Nathalie
    Vermeersch, Marjorie
    Amighi, Karim
    Goole, Jonathan
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 131 : 151 - 151
  • [35] Nose-to-brain delivery of tacrine
    Jogani, Viral V.
    Shah, Pranav J.
    Mishra, Pushpa
    Mishra, Anil Kumar
    Misra, Ambikanandan R.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (09) : 1199 - 1205
  • [36] Nose-to-brain delivery of biologics
    Schwarz, Bettina
    Merkel, Olivia M.
    THERAPEUTIC DELIVERY, 2019, 10 (04) : 207 - 210
  • [37] On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles
    Formica, Maria L.
    Real, Daniel A.
    Picchio, Matias L.
    Catlin, Elise
    Donnelly, Ryan F.
    Paredes, Alejandro J.
    APPLIED MATERIALS TODAY, 2022, 29
  • [38] Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery
    Rinaldi, Federica
    Hanieh, Patrizia N.
    Chan, Lik King Nicholas
    Angeloni, Livia
    Passeri, Daniele
    Rossi, Marco
    Wang, Julie Tzu-Wen
    Imbriano, Anna
    Carafa, Maria
    Marianecci, Carlotta
    PHARMACEUTICS, 2018, 10 (02):
  • [39] Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview
    Musumeci, Teresa
    Bonaccorso, Angela
    Puglisi, Giovanni
    PHARMACEUTICS, 2019, 11 (03)
  • [40] Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery
    Battaglia, Luigi
    Panciani, Pier Paolo
    Muntoni, Elisabetta
    Capucchio, Maria Teresa
    Biasibetti, Elena
    De Bonis, Pasquale
    Mioletti, Silvia
    Fontanella, Marco
    Swaminathan, Shankar
    EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (04) : 369 - 378